{"paper_id":"f9b6ef6e-6a0b-4afa-9296-38a46d35f583","body_text":"conferenceseries.com\nVolume: 00Gynecology & Obstetrics\nPage 8\nReproduction Fertility 2021\nJuly 21, 2021 | Webinar\nJuly 21, 2021 | Webinar\n3rd International Conference on Womens  HealtH , RepR oduction  and  FeRtility\nMariana Robalo Cordeiro et al., Gynecol Obstet (Sunnyvale) 2021, ISSN: 2161-0932\nEndometriosis hidden behind menopause, a new paradigm\nMariana Robalo Cordeiro1, Fernanda Geraldes1, Margarida Figueiredo-Dias1,2\n1 Gynecology Department, Universitary Hospital Center of Coimbra, Portugal\n2 Universitary Clinic of Gynecology, Faculty of Medicine, University of Coimbra, Portugal\nEndometriosis is known to be an estrogen-dependent chronic inflammatory disease, classically characteristic of reproductive-age women. In postmenopausal \npatients it is a rare condition, reported to affect up to 2-5% of women worldwide. The pathophysiologic mechanisms responsible for either the exacerbation of \nprevious undiagnosed disease or the development of de novo endometriotic lesions remain uncertain. Clinical presentation of endometriosis in postmenopausal \nwomen is very unspecific, ranging from asymptomatic to pelvic pain, ovarian cysts and to intestinal symptoms. To date, there are no specific biomarkers identified \nfor the endometriosis diagnosis, even though inflammatory markers and CA-125 levels can be modified, highlighting the need for novel diagnostic biomarkers. \nImaging techniques, such as ultrasound and magnetic resonance imaging can possibly diagnose endometriotic lesions, nevertheless a non-invasive accurate \ndiagnostic method is not yet available. Due to difficulties in diagnosing endometriosis in postmenopausal women, laparoscopic surgery and biopsy of suspicious \nlesions is the gold standard for its definitive diagnosis, having the additional therapeutic potential. The use of menopausal hormone therapy in women with a \nhistory of endometriosis is controversial, and further studies are needed to outweigh its risks and benefits. Besides, the ideal therapeutic approach in de novo \nendometriosis is also not clarified for women after menopause. It is also believed that postmenopausal women with endometriosis have an increased risk for \nmalignant tumours, apart from the ovarian cancer. This presentation pretends to summarize the main updates on the scarce literature related to endometriosis in \npostmenopausal women, which merits full medical attention.\nBiography\nMariana Robalo Cordeiro has completed her Master Degree in Medicine at the age of 24 years from Faculty of Medicine of the University of Coimbra and has a \nPost-graduation in Artificial Intelligence in Healthcare from Massachusetts Institute of Technology. She is a Gynecology and Obstetrics Resident at Universitary \nHospital Center of Coimbra                                                                                                           \nmarianarobalocordeiro@gmail.com","source_license":"CC0","license_restricted":false}